

KCRS24 FINAL AGENDA – All times are in EDT

Thursday, July 11th

- 7:00-11:00am **Registration and Continental Breakfast**
- 7:30-10:30am **RCC Perioperative Trial Collaborative (RCC-PTC)
CLOSED SESSION – Invitation Only for Collaborative Members
Moderated by Axel Bex Royal Free London Hospital &
Grant Stewart, University of Cambridge**
- 11:00-11:15am **KCRS24 Welcome
Bryan Lewis, KidneyCAN President**
- 11:15am-12:00pm **How the Air We Breathe Can Impact Cancer
Keynote: Charles Swanton, The Francis Crick Institute**
- 12:00-1:00pm **Session 1: Exploring Novel Drug Targets for RCC
Moderated by Pavlos Msaouel, MD Anderson Cancer Center &
Scott Tykodi, Fred Hutchinson Cancer Center**
- Purinergic Receptor Antagonist Therapeutics in Treating Metastatic Renal Cancer
 Jean Jiang, University of Texas Health San Antonio
- Identification of Novel Therapeutic Strategies for Chromophobe RCC
 Elizabeth Henske, Brigham & Women's Hospital/Harvard Medical School
- Interrogating the Therapeutic Relevance of Targeting the Antiapoptotic BCL-XL Protein in Kidney Cancer
 Abhishek Chakraborty, Cleveland Clinic Foundation
- SETD2 Deficiency is a Therapeutic Target to Upregulate Viral Mimicry in Treating Aggressive Clear Cell Renal Cell Carcinoma Patients
 Neil Bhowmick, Cedars-Sinai Medical Center
- 1:00-2:15pm **Lunch and Networking**
- 2:15-3:15pm **Session 2: Novel Imaging and Biomarkers to Guide RCC Patient
Management
Moderated by Eric Jonasch, MD Anderson Cancer Center &
Katy Beckermann, Vanderbilt University Medical Center**
- PET Imaging of HIF-2a in Renal Cancer
 Xiankai Sun, University of Texas Southwestern Medical Center
- Multiplexed Quantification of Urinary Biomarkers for Noninvasive Classification of Imaged Kidney Tumors
 Jeremiah Morrissey, Washington University in St. Louis
- Multimodal AI-Based Renal Cancer Patient Care
 Christopher Weight, Cleveland Clinic Foundation
- Shared Heritability Between Renal Cell Carcinoma and Hematopoietic-Related Phenotype
 Valisha Shah, Dana-Farber Cancer Institute

3:15-4:15pm **Session 3: State of the Science**
Moderated by Rohit Mehra, University of Michigan &
Payal Kapur, University of Texas Southwestern Medical Center

Taxonomic Evolution of Kidney Cancer with Emphasis on Molecularly Defined RCC
Samson Fine, Memorial Sloan Kettering Cancer Center

Surgical Pathology Toolbox and Technological Advances to Solve Kidney Cancer Problems
Michelle Hirsch, Brigham & Women's Hospital

Prognostic and Predictive Biomarkers in Kidney Cancer
Payal Kapur, University of Texas Southwestern Medical Center

Sarcomatoid Renal Cell Carcinoma: Diagnostic Updates and Therapeutic Implications
Sabina Signoretti, Brigham and Women's Hospital

Role of Pathologist in Kidney Cancer Diagnostics and Research
Rohit Mehra, University of Michigan

4:15-4:30pm **Afternoon Break**

4:30-5:15pm **Session 4: Trials in Progress**
Moderated by Robert Motzer, Memorial Sloan Kettering Cancer Center &
Naomi Haas, Abramson Cancer Center/University of Pennsylvania

Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)
Michael Serzan, Dana-Farber Cancer Institute

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605
Rana McKay, University of California, San Diego

Phase II Trial of Ubatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma
Pavlos Msaouel, MD Anderson Cancer Center

Pilot Study of an Implantable Microdevice for In Vivo Evaluation of Drug Response in Renal Cell Carcinoma (NCT05700461)
Vincent Xu, Dana-Farber Cancer Institute

INTerpath-004: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab with V940 (mRNA-4157) or Placebo in the Adjuvant Treatment of Renal Cell Carcinoma
Toni Choueiri, Dana-Farber Cancer Institute

WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer
Grant Stewart, University of Cambridge

5:15-5:30pm **Awards Announcement and Closing**

- AACR-KidneyCAN Innovation and Discovery Grant Awards
- KCRS24 Merit Awards
- KCRS24 Outstanding Research Awards
- KCRS24 Hall of Fame Award

Bryan Lewis, KidneyCAN President

5:30-6:30pm **Posters and Prosecco**
Ari Hakimi, Memorial Sloan Kettering Cancer Center, Poster Walk



6:30-8:30pm Reception – Smith & Wollensky (next door to the InterContinental)

Friday, July 12th

6:00-7:00am Rock the Run 5K

7:00-8:00am Registration and Breakfast

8:00-8:15am KCRS24 Welcome
Bryan Lewis, KidneyCAN President

8:15-8:45am Obesity and Immunotherapy
Featured Speaker: Jeffrey Rathmell, Vanderbilt University Medical Center

8:45-10:15am Session 5: Clinical and Scientific Updates in Kidney Cancer
Moderated by Toni Choueiri, Dana-Farber Cancer Institute

Front Line Systemic Therapy Strategies
Tom Powles, Barts Cancer Centre

Subsequent Line Treatments for Advanced Disease
Robert Motzer, Memorial Sloan Kettering Cancer Center

Adjuvant Treatment Options
Bradley McGregor, Dana-Farber Cancer Institute

Strategies for Patients with Non-Clear Cell RCC
Laurence Albiges, Institut Gustave-Roussy

Novel Therapies Outside Immunotherapy
Rana McKay, University of California, San Diego

Novel Immunotherapy Strategies
David Braun, Yale Cancer Center

10:15-10:45am Coffee Break

10:45-12:00pm Session 6: Immunotherapy Advances and Research
Moderated by Hans Hammers, University of Texas Southwestern Medical Center & David McDermott, Beth Israel Deaconess

Overview in Development of Immunotherapy for Kidney Cancer
Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center

Mechanisms and Predictors of Adoptive Cytokine-Induced Memorylike NK Cell Therapy in Renal Cell Carcinoma
Rizwan Romee, Dana-Farber Cancer Institute

Delineate Tumor-Immune Contexture That Shapes ccRCC Metastatic Progression and Response to Immunotherapy
Srinivas Malladi, University of Texas Southwestern Medical Center

Inhibiting PTPN2/PTPN1: A New Option for Immunotherapy
Jonathan Powell, Calico Labs



Uncovering the Tumor-Immune Microenvironmental Determinants of Immunotherapy Response in Renal Cell Carcinoma Through Ex Vivo Patient-Derived Models

David Braun, Yale School of Medicine

12:00-1:00pm Lunch and Networking

1:00-2:15pm Session 7: Oral Abstract Presentations
Moderated by Rana McKay, University of California, San Diego & Yuksel Urun, Ankara University School of Medicine

Belzutifan Versus Everolimus for Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 LITESPARK-005 Study

Laurence Albiges, Institut Gustave-Roussy

Safety Profile of Belzutifan Monotherapy in Patients with Renal Cell Carcinoma: A Pooled Analysis of 4 Clinical Trials

Toni Choueiri, Dana-Farber Cancer Institute

CDK4/6 Inhibition with Abemaciclib in Patients (pts) With Previously Treated Advanced Renal Carcinoma (RCC)

Bradley McGregor, Dana-Farber Cancer Institute

Association of a Germline Single Nucleotide Polymorphism (SNP) in the Interleukin-7 (IL7) Gene with Immune-Related Adverse Events (irAEs)

Eddy Saad, Dana-Farber Cancer Institute

Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid Renal Cell Carcinoma

Karl Semaan, Dana-Farber Cancer Institute

Impact of CBM588 on Gut Microbiome Composition and Dysbiosis in Patients Receiving Frontline Immune Checkpoint Inhibitor (ICI) Combinations for Metastatic Renal Cell Carcinoma (mRCC)

Nazli Dizman, MD Anderson Cancer Center

2:15-2:45pm Afternoon Break

2:45-3:45pm Session 8: Rapid Abstract Presentations
Moderated by Sumanta Pal, City of Hope Comprehensive Cancer Center & Evita Sadimin, City of Hope Comprehensive Cancer Center

Enrichment of Tertiary Lymphoid Structures Provides Novel Insight into Mediators of Anti-Tumor Immune Activity in Sarcomatoid Renal Cell Carcinoma

Nicholas Salgia, Roswell Park Comprehensive Cancer Center

Tumor Evolution of Brain-Specific Tropism in Metastatic Renal Cell Carcinoma

Roy Elias, Johns Hopkins

Impact of Latino Ethnicity on the Gut Microbiome Composition of Patients with Metastatic Renal Cell Cancer (mRCC)

Regina Barragan-Carrillo, City of Hope Comprehensive Cancer Center

Natural Killer Cells Have Impaired Cytotoxicity in Advanced Renal Cell Carcinoma

Vivien Moritz, Yale School of Medicine

Development of an Ex Vivo Patient-Derived Tumor Model (PDTM) to Assess the Tumor Microenvironment in Renal Cell Carcinoma (RCC)

Soki Kashima, Yale School of Medicine



Fasting Mediated Gut Microbiome Modulation Improves Response to Immune Checkpoint Therapy in Renal Cell Cancer

Shahla Bari, Duke University

Ferroptosis Suppressor Protein 1 is a Potent and Targetable Inhibitor of Ferroptosis in Chromophobe Renal Cell

Samer Salem, Brigham and Women's Hospital

Concordance Analysis of Tissue and Circulating Tumor DNA (ctDNA) in Renal Cell Carcinoma (RCC): Insights from a Multimodal Real-World Database

Chinmay Jani, Sylvester Comprehensive Cancer Center

Evaluating Intermediate Endpoints for Overall Survival in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: An IMDC Study

Renee Marie Saliby, Dana-Farber Cancer Institute

A Phase 1 Study of Fianlimab (Anti-LAG-3) in Combination with Cemiplimab (Anti-PD-1) in Patients with Advanced ccRCC

Miso Kim, Seoul National University Hospital

3:45-4:00pm **Break**

4:00-5:30pm **Special Session: Biotech Showcase**
Moderated by Tom Powles, Barts Cancer Centre &
Hans Hammers, University of Texas Southwestern Medical Center

Casdatifan (AB521): A Hif-2-alpha Inhibitor in Development for ccRCC

Dimitry Nuyten, Arcus Biosciences, Chief Medical Officer

Phase 1 Study Results of SRK-181 (Linavonkibart), A Latent TGFβ1 Inhibitor, Combined with Pembrolizumab in Anti-PD1 Resistant ccRCC Patients

Lu Gan, Scholar Rock, VP of Oncology Clinical Development

STK-012, a First-in-Class α/β IL-2 Receptor Biased Partial Agonist in Advanced Solid Tumors

Alex Azrilevich, Synthekine, Inc., Vice President, Oncology Clinical Development

819-01 Study: A Novel Bispecific Antibody Targeting ENPP3 in ccRCC

Chet Bohac, Xencor, Executive Medical Director

AB-2100: A Novel Investigational Cell Therapy for Clear Cell Renal Cell Carcinoma

Levi Gray-Rupp, ArsenalBio, Senior Director, Immunology

Comprehensive Genomic and Transcriptomic Profiling to Identify Distinct Therapeutic Targets for Renal Cell Carcinoma Subtypes: The Renal Medullary Carcinoma Paradigm

Pavlos Msaouel, BostonGene, Principal Investigator

Emerging Therapies in RCC: A Precision Theranostic Approach

Kim Allman, Telix, Medical Director

Empowering High-Parameter Spatial Biology with Imaging Mass Cytometry™

Natasha Lucero, Standard BioTools, Imaging Mass Cytometry Field Application Scientist

5:30-5:40pm **KCRS24 Closing**
Bryan Lewis, KidneyCAN President